mantle cell lymphoma presenting as bullous pemphigoid a rare paraneoplastic syndrome

Original title: “Mantle cell lymphoma presenting as bullous pemphigoid: a rare paraneoplastic syndrome.”

Acalabrutinib combinations approved for CLL and MCL

Original title: “NICE backs new blood cancer regimens”

Beqalzi is the first BCL2 inhibitor approved for relapsed or refractory mantle cell lymphoma.

Original title: “BeOne wins mantle cell lymphoma approval, opening new therapy class”

This will help us accelerate promising therapies, and build toward our ultimate goal of running real-time, continuous trials across all phases of drug development.” · The FDA is announcing the successful initiation of proof-of-concept RTCTs by AstraZeneca and Amgen. AstraZeneca is conducting a Phase 2 multi-site trial, TRAVERSE, in patients with treatment... This will help us accelerate promising therapies, and build toward our ultimate goal of running real-time, continuous trials across all phases of drug development.” · The FDA is announcing the successful initiation of proof-of-concept RTCTs by AstraZeneca and Amgen. AstraZeneca is conducting a Phase 2 multi-site trial, TRAVERSE, in patients with treatment-naïve mantle cell lymphoma, with participation from The University of Texas MD Anderson Cancer Center and University of Pennsylvania. We demonstrated that it is not only possible, but also potentially transformative for the clinical trials ecosystem,” said Chief AI Officer Jeremy Walsh. “We have to consider our processes from the standpoint of a patient awaiting a potentially powerful treatment.” White Oak, Md., April 28, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today announced two major steps as part of an initiative to advance the implementation of real-time clinical trials (RTCT). First, the agency unveiled the successful initiation of two proof-of-concept clinical trials that will report endpoints and data signals to the agency in real time. Early-phase clinical trials are a bottleneck in drug development, often characterized by high uncertainty, limited patient populations, and inefficient decision-making processes. Data is typically reported from sites to sponsors, who analyze and subsequently submit data to the FDA.

Original title: “FDA Announces Major Steps to Implement Real-Time Clinical Trials - BioSpace”

cutaneous acral presentation of indolent mantle cell lymphoma with prominent nail involvement and atypical immunophenotype

Original title: “Cutaneous Acral Presentation of Indolent Mantle Cell Lymphoma With Prominent Nail Involvement and Atypical Immunophenotype.”

tailored approaches in mantle cell lymphoma refining treatment paradigms with an expert panel opinion

Original title: “Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion.”

ATALANTA-1 data presented at ASH 2025 showed remarkable response rates and rapid manufacturing with an investigational autologous CAR T-cell therapy. ATALANTA-1 data presented at ASH 2025 showed remarkable response rates and rapid manufacturing with an investigational autologous CAR T-cell therapy. ... ASH 2025 data on the phase 2 TrAVeRse study evaluating acalabrutinib, venetoclax, and rituximab (AVR) in treatment-naive disease. He views AVR as a clear example of how frontline, chemo-free therapy may offer patients durable disease control with substantially reduced toxicity, positioning such regimens as a new standard of care for treatment-naive MCL. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics. Wang traces the field’s progress and how the advent of BTK inhibitors—beginning with ibrutinib and followed by newer-generation agents such as acalabrutinib—marked a turning point by delivering high response rates with oral therapy and substantially less toxicity. The addition of venetoclax further deepened responses, laying the groundwork for combination strategies capable of rivaling, and in some cases surpassing, outcomes historically achieved with chemotherapy. The TrAVeRse trial confirmed earlier single-center and smaller studies, demonstrating nearly universal overall response rates and complete response rates approaching 80%. These outcomes were consistent across risk groups, reinforcing the robustness of the regimen.

Original title: “Moving From Chemotherapy to Chemo-Free Frontline Care in MCL | AJMC”